Top-Rated StocksTop-RatedNASDAQ:AAPG Ascentage Pharma Group International (AAPG) Stock Price, News & Analysis $12.01 -0.43 (-3.46%) Closing price 11/20/2026 03:57 PM EasternExtended Trading$11.66 -0.35 (-2.87%) As of 11/20/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC FilingsShort Interest About Ascentage Pharma Group International Stock (NASDAQ:AAPG) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AAPG alerts:Sign Up Key Stats Today's Range$11.97▼$12.2650-Day Range$12.01▼$16.4652-Week Range$11.97▼$33.09Volume5,039 shsAverage Volume7,062 shsMarket Capitalization$1.13 billionP/E RatioN/ADividend YieldN/APrice Target$43.44Consensus RatingBuy Company Overview Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases. Its research focuses on therapies that target mechanisms involved in programmed cell death, or apoptosis, to help prevent cancer cells from surviving and multiplying. The company's two approved oncology drugs in China are olverembatinib, used to treat certain forms of leukemia, and lisaftoclax (APG-2575), a BCL-2 inhibitor approved for certain patients with chronic lymphocytic leukemia and small lymphocytic lymphoma. Its pipeline also includes alrizomadlin (APG-115), an investigational cancer treatment, and additional drug candidates targeting pathways involved in cancer cell survival. Ascentage conducts research and clinical-development activities in China and internationally, including in the United States. While some of its drugs are already approved in China, others remain subject to clinical testing and regulatory review, and approved uses may vary by geography. The company's American Depositary Shares trade on the Nasdaq Global Market under the symbol AAPG, while its ordinary shares are listed on the Hong Kong Stock Exchange under stock code 6855. AI Generated. May Contain Errors. Read More Ascentage Pharma Group International Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks91st Percentile Overall ScoreAAPG MarketRank™: 4.562289562285 of 5 starsAscentage Pharma Group International scored higher than 91% of companies evaluated by MarketBeat, and ranked 26th out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.6 / 5Analyst RatingBuy Consensus RatingAscentage Pharma Group International has received a consensus rating of Buy. The company's average rating score is 3.15, and is based on 2 strong buy ratings, 11 buy ratings, no hold ratings, and no sell ratings.Upside PotentialAscentage Pharma Group International has a consensus price target of $43.44, representing about 261.7% upside from its current price of $12.01.Amount of Analyst CoverageAscentage Pharma Group International has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ascentage Pharma Group International's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Ascentage Pharma Group International are expected to grow in the coming year, from ($2.43) to ($0.41) per share.Price to Book Value per Share RatioAscentage Pharma Group International has a P/B Ratio of 5.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.01% of the float of Ascentage Pharma Group International has been sold short.Short Interest Ratio / Days to CoverAscentage Pharma Group International has a short interest ratio ("days to cover") of 1.03, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ascentage Pharma Group International has recently decreased by 49.75%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAscentage Pharma Group International does not currently pay a dividend.Dividend GrowthAscentage Pharma Group International does not have a long track record of dividend growth. News and Social Media4.1 / 5News Sentiment0.52 News SentimentAscentage Pharma Group International has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Ascentage Pharma Group International this week, compared to 3 articles on an average week.Search Interest3 people have searched for AAPG on MarketBeat in the last 30 days. MarketBeat Follows6 people have added Ascentage Pharma Group International to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Ascentage Pharma Group International insiders have not sold or bought any company stock.Percentage Held by InstitutionsAscentage Pharma Group International has minimal institutional ownership at this time.Read more about Ascentage Pharma Group International's insider trading history. Receive AAPG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ascentage Pharma Group International and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AAPG Stock News HeadlinesBTIG Research Reaffirms Buy Rating for Ascentage Pharma Group International (NASDAQ:AAPG)November 19 at 1:24 AM | americanbankingnews.comAscentage Pharma's Lisaftoclax, Olverembatinib Secure Coverage Under China's 2026 NRDLNovember 16, 2026 | rttnews.comCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savings account… The digital dollar is inevitable. Think about what this means... When the digital dollar goes live, every dollar you saved could suddenly be trackable at the transaction level. Imagine the worst case scenario: You’re now subject to new digital withdrawal limits and spending restrictions. Your account can be frozen remotely without court approval. But here's what Bank of America didn't say: There's still a way to protect your wealth before this digital prison locks. While everyone else gets trapped in the digital system, my research team has been positioning members outside that reach… completely under their own control. No government tracking. No withdrawal limits. No remote freezing.November 22 at 1:00 AM | Decentralized Masters (Ad)Ascentage Pharma Announces Inclusion of Lisaftoclax in China's 2026 National Reimbursement Drug List and Successful Renewal of Coverage for OlverembatinibNovember 15, 2026 | globenewswire.comAscentage Pharma to Present Data from Multiple Trials, Including an Oral Presentation of APG-5918 at ASH 2026November 4, 2026 | globenewswire.comAscentage Pharma to Participate in Two Upcoming Investor Conferences in LondonNovember 3, 2026 | globenewswire.comAscentage Pharma's Lisaftoclax Granted China Breakthrough DesignationOctober 22, 2026 | finance.yahoo.comAscentage Pharma’s Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLLOctober 22, 2026 | markets.businessinsider.comSee More Headlines AAPG Stock Analysis - Frequently Asked Questions How have AAPG shares performed this year? Ascentage Pharma Group International's stock was trading at $26.24 at the start of the year. Since then, AAPG shares have decreased by 54.2% and is now trading at $12.01. When did Ascentage Pharma Group International IPO? Ascentage Pharma Group International (AAPG) raised $126 million in an IPO on Friday, January 24th 2025. The company issued 7,325,000 shares at a price of $17.25 per share. How do I buy shares of Ascentage Pharma Group International? Shares of AAPG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/19/2026Today11/22/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:AAPG Previous SymbolNASDAQ:AAPG CIK2023311 Webwww.ascentage.cn Phone86 512 8555 7777FaxN/AEmployees767Year Founded2017Price Target and Rating Average Price Target for Ascentage Pharma Group International$43.44 High Price Target$51.00 Low Price Target$33.00 Potential Upside/Downside+261.7%Consensus RatingBuy Rating Score (0-4)3.15 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio1.09 Current Ratio1.22 Quick Ratio1.18 Sales & Book Value Annual Sales$642.64 million Price / Sales1.75 Cash FlowN/A Price / Cash FlowN/A Book Value$2.04 per share Price / Book5.89Miscellaneous Outstanding Shares93,741,000Free FloatN/AMarket Cap$1.13 billion OptionableN/A Beta0.21 The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:AAPG) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredThe warning signs most investors see too lateDr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. ...Weiss Ratings | SponsoredYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascentage Pharma Group International - Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascentage Pharma Group International With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.